CoChat

A 6‐month, randomized, double‐blind, placebo‐controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease

Open access
Devanand, D.P., Pelton, Gregory H., Cunqueiro, Karine, Sackeim, Harold A., Marder, Karen · 2011 · International Journal of Geriatric Psychiatry
Cited by 65

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. Methods: In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of haloperidol (0.5–5 mg daily) were randomized to a 24‐week, double‐blind pilot trial of discontinuation on placebo versus continuation haloperidol. Phase A response criteria were minimum 50% reduction in three target symptoms, and improvement on the Clinical Global Impression‐Change (CGI‐C) score for psychosis/agitation. Phase B relapse criteria required 50% worsening in target symptoms and on the CGI‐C. α = 0.1 was the significance criterion in this pilot study. Results: Of 44 patients, 22 patients responded in Phase A. The sum score of target symptoms, and Brief Psychiatric Rating Scale (BPRS) psychosis and hostile suspiciousness factor scores, decreased in Phase A (p's < 0.001). Extrapyramidal signs increased in Phase A (p < 0.01). Of 22 responders, 21 patients entered Phase B, and 20 had at least one follow‐up visit. Four of 10 patients (40%) on continuation haloperidol relapsed compared to eight of 10 patients on placebo (80%, χ2 = 3.3, p = 0.07). In survival analyses, time to relapse was shorter on placebo than haloperidol (χ2 = 4.1, p = 0.04). Conclusions: Haloperidol open treatment was efficacious, and relapse was greater on placebo than with haloperidol continuation. In patients with AD who have psychosis or agitation and respond to antipsychotic medication, the increased risk of relapse after discontinuation needs to be weighed against the side effects associated with continuing the medication. Copyright © 2010 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.2630

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 65

Metadata

Authors
Devanand, D. P., Pelton, G. H., Cunqueiro, K., Sackeim, H. A., & Marder, K.
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2010-12-28
Volume
26
Issue
9
Pages
937-943
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W1968770674
Cited by
65
References
10
FWCI
4.19
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.